Zhejiang Zhixin Pharmaceutical Technology

Zhejiang Zhixin Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, focused on the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company leverages its proprietary drug discovery platform to target critical signaling pathways, aiming to provide more effective treatment options for patients with unmet medical needs. Its lead candidate, ZX-101, is a dual PI3K/mTOR inhibitor currently in Phase 1/2 clinical trials for hematological malignancies and solid tumors. Additionally, Zhixin Pharma is advancing ZX-401, a selective JAK1 inhibitor, for the treatment of various inflammatory conditions. The company is backed by prominent venture capital firms and maintains a robust pipeline of early-stage assets.